MCM
MYGN icon

Marathon Capital Management’s Myriad Genetics MYGN Stock Holding History

Marathon Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-79,460
Closed -$2.21M – 114
2019
Q2 		$2.21M Buy
+79,460
New +$2.24M 0.9% 19
2018
Q4 		– Sell
-5,000
Closed -$230K – 115
2018
Q3 		$230K Buy
+5,000
New +$222K 0.09% 91

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marathon Capital Management's MYGN Position: Q3 2019 in Review

Marathon Capital Management sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 79,460 shares — an estimated $2.21M sold.

Marathon Capital Management first reported a position in MYGN in Q3 2018 and held it in 2 quarters. The position peaked at $2.21M in Q2 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Marathon Capital Management reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Marathon Capital Management sold 79,460 Myriad Genetics shares in Q3 2019, an estimated $2.21M.
  • Marathon Capital Management first reported a position in Myriad Genetics in Q3 2018 and held it in 2 quarters.
  • Marathon Capital Management's Myriad Genetics position peaked at $2.21M in Q2 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Marathon Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.